Ocata Therapeutics Inc fka OCAT

[rocky301]

The continuing mail suggests many are confused with our relationships with CHA. I will try again to separate and clarify. Break it down in 2 sections, (1)JV and (2)Exclusive license agreements strictly for S.Korea

Joint Venture: SCRMI Stem Cell and Regenerative Medicine International
CHA holds a 60% interest, ACT 40%
Hemangioblast and Induced Pluripotent Stem Cells
Transfusable Blood Components:
Vascular Repair Cells:
http://www.steminternational.com/

License Agreement #1
RPE Technology for trials and commercialization in S.Korea
Total amount possible was $1.9MM...$1.4MM already paid
Numbers broken down here, http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54720295

License Agreement #2
Blastomere Technology
Exclusive License to use and commercialize the Single Blastomere Technology in South Korea.
Total amount of $300K already paid.